Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital
Spruce Biosciences, Inc. (SPRB)
Company Research
Source: Business Wire
Initial Funding of $15 Million from the First of Four Tranches, Extending Cash Runway into 2027Facility Will Support Advancement and Potential Launch of TA-ERT for the Treatment of MPS IIIB SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Spruce) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that, on January 7, 2026, it entered into a loan facility with Avenue Venture Opportunities Fund II, L.P., a fund of Avenue Capital Group (Avenue Capital), for up to $50 million in growth capital.The loan facility has a 42-month term and includes an initial tranche of $15 million, which will be fully funded on or around January 9, 2026, and three additional tranches totaling up to $35 million, the funding of which is subject to the satisfaction of certain terms and conditions of the loan and security agreement, including the ac
Show less
Read more
Impact Snapshot
Event Time:
SPRB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SPRB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SPRB alerts
High impacting Spruce Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
SPRB
News
- Spruce Biosciences (NASDAQ:SPRB) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SPRB&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreMarketBeat
- Spruce Biosciences (NASDAQ:SPRB) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating on the stock.MarketBeat
- Spruce Biosciences (NASDAQ:SPRB) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $220.00 price target on the stock.MarketBeat
- Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors [Yahoo! Finance]Yahoo! Finance
- Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of DirectorsBusiness Wire
SPRB
Sec Filings
- 1/8/26 - Form 8-K
- 1/5/26 - Form 4
- 12/17/25 - Form 4
- SPRB's page on the SEC website